ProQR (PRQR)
NASDAQ:PRQR
PRQR Stock Chart & Stats
$1.62
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.62
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.07 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$170.68M
Enterprise Value$69.03M
Total Cash (Recent Filing)$92.37M
Total Debt (Recent Filing)$13.99M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Apr 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue4.34
Enterprise Value/Gross Profit4.53
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$8.20Price Target Upside406.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$21.92M
Bulls Say, Bears Say
Bulls Say
Platform Breadth (Axiomer)ProQR’s Axiomer platform now supports multiple development candidates across distinct indications (AX-0810, AX-2402, AX-2911). This diversification spreads R&D risk, increases potential value capture from multiple programs, and strengthens long-term franchise optionality as candidates advance.
Clinical De-risking Of Lead AssetEarly Phase 1 safety and pharmacokinetics that match preclinical expectations materially reduce near-term development risk for AX-0810. Upcoming target engagement and planned patient cohort could provide pivotal proof-of-concept signals that sustainably change clinical and partnering prospects over the coming months.
Near-term Funding Support And RunwayA reported cash balance and milestone receipts from partners extend runway into mid-2027, enabling planned clinical work and candidate selection without immediate dilution. External funding for specific programs and collaboration milestones reduce near-term financing pressure and support execution of 2026 plans.
Bears Say
Persistent Cash BurnProQR’s recurring negative operating and free cash flow indicate a structurally cash-consuming business model while advancing clinical programs. Continued burn elevates the probability of future capital raises, which can dilute shareholders and constrain strategic flexibility if clinical readouts or partner funding don’t materialize.
Declining Shareholders' EquityA material decline in equity weakens the company’s balance-sheet buffer against further losses, potentially limiting debt capacity and increasing reliance on equity financing. This structural deterioration raises governance and funding risks that can persist across multiple quarters absent a reversal in profitability or large partner inflows.
Revenue Volatility And Ongoing LossesAlthough revenue had grown historically, the sharp 2025 decline and persistent operating losses show weak operating leverage and unpredictability in commercial traction or milestone timing. This structural volatility complicates planning, heightens financing needs, and leaves the path to sustainable margins uncertain.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.07 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $170.68M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Apr 30, 2026 which is in 28 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Mar 12, 2026. The company reported -$0.092 earnings per share for the quarter, beating the consensus estimate of -$0.103 by $0.01.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.14.
How many shares outstanding does ProQR have?
ProQR has 105,361,060 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.092 in its last earnings report, beating expectations of -$0.103. Following the earnings report the stock price went down -4.972%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.20 (406.17% Upside)
$8.20 (406.17% Upside)
Hedge Fund Trend
Decreased
By 92.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 63.3%
Last 30 Days ▲ 64.6%
Last 30 Days ▲ 64.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-99.45%
Trailing 12-Months
Asset Growth
27.61%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.20
▲(406.17% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.35% Mutual Funds
24.85% Other Institutional Investors
72.40% Public Companies and
Individual Investors